FDA approves Tukysa for first-line HER2+ breast cancer treatment

🇺🇸 Investing.com (US) —
FDA approves Tukysa for first-line HER2+ breast cancer treatment

AI Summary

The FDA has approved Tukysa for first-line treatment of HER2-positive breast cancer. The article provides no additional details about the approval or eligible patients.

Markets Health FDA approval Tukysa breast cancer HER2-positive first-line treatment

Read original source →